Guggenheim Capital’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $28.7M | Buy |
45,969
+3,060
| +7% | +$2.08M | 0.18% | 104 |
|
|
2026
Q1 | $33.2M | Sell |
42,909
-2,009
| -4% | -$1.54M | 0.26% | 81 |
|
|
2025
Q4 | $34.7M | Buy |
44,918
+2,610
| +6% | +$1.77M | 0.25% | 77 |
|
|
2025
Q3 | $23.8M | Buy |
42,308
+2,076
| +5% | +$1.17M | 0.17% | 117 |
|
|
2025
Q2 | $21.1M | Buy |
40,232
+7,166
| +22% | +$4M | 0.17% | 110 |
|
|
2025
Q1 | $21M | Sell |
33,066
-4,547
| -12% | -$3.13M | 0.19% | 105 |
|
|
2024
Q4 | $26.8M | Sell |
37,613
-751
| -2% | -$630K | 0.22% | 90 |
|
|
2024
Q3 | $40.3M | Sell |
38,364
-5,228
| -12% | -$5.82M | 0.28% | 67 |
|
|
2024
Q2 | $45.8M | Buy |
43,592
+2,239
| +5% | +$2.17M | 0.32% | 56 |
|
|
2024
Q1 | $39.8M | Sell |
41,353
-1,591
| -4% | -$1.51M | 0.28% | 67 |
|
|
2023
Q4 | $37.7M | Buy |
42,944
+3,403
| +9% | +$2.8M | 0.29% | 66 |
|
|
2023
Q3 | $32.5M | Buy |
39,541
+913
| +2% | +$718K | 0.28% | 67 |
|
|
2023
Q2 | $27.8M | Sell |
38,628
-3,337
| -8% | -$2.57M | 0.22% | 82 |
|
|
2023
Q1 | $34.5M | Sell |
41,965
-8,087
| -16% | -$6.1M | 0.29% | 58 |
|
|
2022
Q4 | $36.1M | Sell |
50,052
-4,463
| -8% | -$3.29M | 0.32% | 60 |
|
|
2022
Q3 | $37.6M | Sell |
54,515
-8,197
| -13% | -$5.16M | 0.34% | 50 |
|
|
2022
Q2 | $37.1M | Sell |
62,712
-4,079
| -6% | -$2.65M | 0.29% | 60 |
|
|
2022
Q1 | $46.6M | Sell |
66,791
-10,846
| -14% | -$6.86M | 0.28% | 60 |
|
|
2021
Q4 | $49M | Buy |
77,637
+7,166
| +10% | +$4.41M | 0.26% | 69 |
|
|
2021
Q3 | $42.6M | Sell |
70,471
-8,973
| -11% | -$5.57M | 0.26% | 63 |
|
|
2021
Q2 | $44.4M | Buy |
79,444
+11,343
| +17% | +$5.75M | 0.26% | 60 |
|
|
2021
Q1 | $32.2M | Buy |
68,101
+2,951
| +5% | +$1.44M | 0.21% | 85 |
|
|
2020
Q4 | $31.5M | Sell |
65,150
-70
| -0.1% | -$37.8K | 0.2% | 86 |
|
|
2020
Q3 | $36.5M | Sell |
65,220
-4,481
| -6% | -$2.72M | 0.26% | 63 |
|
|
2020
Q2 | $43.5M | Sell |
69,701
-5,619
| -7% | -$3.19M | 0.34% | 47 |
|
|
2020
Q1 | $36.8M | Sell |
75,320
-14,185
| -16% | -$5.85M | 0.37% | 39 |
|
|
2019
Q4 | $33.6M | Buy |
89,505
+706
| +0.8% | +$238K | 0.25% | 69 |
|
|
2019
Q3 | $24.6M | Buy |
88,799
+18,763
| +27% | +$5.55M | 0.2% | 103 |
|
|
2019
Q2 | $21.9M | Buy |
70,036
+2,808
| +4% | +$935K | 0.18% | 116 |
|
|
2019
Q1 | $27.6M | Buy |
67,228
+6,107
| +10% | +$2.51M | 0.23% | 75 |
|
|
2018
Q4 | $22.8M | Sell |
61,121
-10,401
| -15% | -$3.81M | 0.19% | 86 |
|
|
2018
Q3 | $28.9M | Sell |
71,522
-2,416
| -3% | -$919K | 0.19% | 77 |
|
|
2018
Q2 | $25.5M | Sell |
73,938
-145,747
| -66% | -$45.6M | 0.17% | 89 |
|
|
2018
Q1 | $75.7M | Buy |
219,685
+2,352
| +1% | +$818K | 0.18% | 109 |
|
|
2017
Q4 | $81.7M | Buy |
217,333
+56,829
| +35% | +$23M | 0.19% | 87 |
|
|
2017
Q3 | $71.8M | Buy |
160,504
+297
| +0.2% | +$141K | 0.17% | 105 |
|
|
2017
Q2 | $78.7M | Sell |
160,207
-9,524
| -6% | -$4.17M | 0.21% | 71 |
|
|
2017
Q1 | $65.8M | Buy |
169,731
+5,743
| +4% | +$2.13M | 0.18% | 120 |
|
|
2016
Q4 | $60.2M | Sell |
163,988
-40,848
| -20% | -$15.5M | 0.17% | 124 |
|
|
2016
Q3 | $82.3M | Buy |
204,836
+5,594
| +3% | +$2.24M | 0.26% | 38 |
|
|
2016
Q2 | $69.6M | Buy |
199,242
+7,906
| +4% | +$3.04M | 0.22% | 68 |
|
|
2016
Q1 | $69M | Sell |
191,336
-15,640
| -8% | -$6.44M | 0.22% | 65 |
|
|
2015
Q4 | $112M | Sell |
206,976
-60,888
| -23% | -$33M | 0.33% | 16 |
|
|
2015
Q3 | $125M | Sell |
267,864
-1,258
| -0.5% | -$676K | 0.38% | 11 |
|
|
2015
Q2 | $137M | Buy |
269,122
+3,768
| +1% | +$1.84M | 0.34% | 13 |
|
|
2015
Q1 | $120M | Buy |
265,354
+26,365
| +11% | +$11.2M | 0.28% | 21 |
|
|
2014
Q4 | $98M | Sell |
238,989
-8,526
| -3% | -$3.35M | 0.25% | 40 |
|
|
2014
Q3 | $89.2M | Buy |
247,515
+1,467
| +0.6% | +$492K | 0.21% | 53 |
|
|
2014
Q2 | $69.5M | Sell |
246,048
-58,996
| -19% | -$17.5M | 0.18% | 97 |
|
|
2014
Q1 | $91.6M | Buy |
305,044
+91,544
| +43% | +$28.2M | 0.26% | 34 |
|
|
2013
Q4 | $58.8M | Sell |
213,500
-6,635
| -3% | -$1.91M | 0.18% | 93 |
|
|
2013
Q3 | $68.9M | Buy |
220,135
+18,610
| +9% | +$4.9M | 0.25% | 39 |
|
|
2013
Q2 | $45.3M | Buy |
+201,525
| New | +$46.9M | 0.19% | 68 |
|
Other funds holding REGN
Guggenheim Capital's REGN Position: Q2 2026 in Review
Guggenheim Capital increased its Regeneron Pharmaceuticals (REGN) stake by 7.1% in Q2 2026, buying an estimated $2.08M and bringing the position to 45,969 shares worth $28.7M. The position accounts for 0.18% of the portfolio, ranked #104.
Guggenheim Capital first reported a position in REGN in Q2 2013 and has held it in 53 quarters since. The position peaked at $137M in Q2 2015. 1,332 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- Guggenheim Capital held 45,969 shares of Regeneron Pharmaceuticals worth $28.7M as of Q2 2026.
- Guggenheim Capital bought 3,060 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $2.08M.
- Regeneron Pharmaceuticals made up 0.18% of Guggenheim Capital's portfolio in Q2 2026, its #104 holding.
- Guggenheim Capital first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
- Guggenheim Capital's Regeneron Pharmaceuticals position peaked at $137M in Q2 2015.
- 1,332 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on Guggenheim Capital's 13F filing for Q2 2026, filed 12 Aug 2026.